Compare IT & EXAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IT | EXAS |
|---|---|---|
| Founded | 1979 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.8B | 19.3B |
| IPO Year | 1993 | N/A |
| Metric | IT | EXAS |
|---|---|---|
| Price | $231.46 | $102.25 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 10 | 19 |
| Target Price | ★ $309.67 | $84.27 |
| AVG Volume (30 Days) | 823.6K | ★ 2.1M |
| Earning Date | 02-03-2026 | 02-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 11.49 | N/A |
| Revenue | ★ $6,459,775,000.00 | $3,082,033,000.00 |
| Revenue This Year | $6.71 | $19.40 |
| Revenue Next Year | $3.35 | $13.51 |
| P/E Ratio | $20.63 | ★ N/A |
| Revenue Growth | 5.24 | ★ 14.47 |
| 52 Week Low | $221.16 | $38.81 |
| 52 Week High | $584.01 | $102.66 |
| Indicator | IT | EXAS |
|---|---|---|
| Relative Strength Index (RSI) | 44.21 | 78.48 |
| Support Level | $221.16 | $102.00 |
| Resistance Level | $252.63 | $102.66 |
| Average True Range (ATR) | 8.14 | 0.32 |
| MACD | -1.52 | -0.52 |
| Stochastic Oscillator | 33.78 | 66.38 |
Gartner Inc provides independent research and analysis on information technology and other related technology industries. Its research is delivered to clients' desktops in the form of reports, briefings, and updates. Typical clients are chief information officers and other business executives who help plan companies' IT budgets. Gartner also provides consulting services. The company operates through three business segments, namely Research, Conferences and Consulting. The company generates majority of the revenue from Research segment.
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.